LYTIR

Company · ANTX

AN2 Therapeutics, Inc.

Nasdaq's symbol directory lists ANTX on Nasdaq as “AN2 Therapeutics, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($12K); insiders sold on 5 occasions ($258K).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $12K in total; Insider sales: $258K in total.Jul: Insider sales $25KAug: Insider sales $213KSep: Insider purchases $12KSep: Insider sales $8KNov: Insider sales $12KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $12KInsider sales below: $258K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Readnour Robin Shane sold on 2 days all under a 10b5-1 plan latest Sep 9, 2026 sold $219K
  2. Eizen Joshua M, Chief Operating Officer and Chief Legal Officer sold on 2 days latest Nov 5, 2026 sold $37K
  3. Margaret M. FitzPatrick bought on 1 day latest Sep 1, 2026 bought $12K
  4. Williams Sarah Joanne, Principal Accounting Officer sold on 1 day latest Sep 1, 2026 sold $2K
Every trade (6)
  1. SELLEizen Joshua M, Chief Operating Officer and Chief Legal Officer sold Nov 5, 2026 2,826 shares filing $12K
  2. SELLReadnour Robin Shane sold Sep 9, 2026 1,108 shares 2 legs combined 10b5-1 plan (scheduled) filing $7K
  3. BUYMargaret M. FitzPatrick bought Sep 1, 2026 2,098 shares filing $12K
  4. SELLWilliams Sarah Joanne, Principal Accounting Officer sold Sep 1, 2026 272 shares filing $2K
  5. SELLReadnour Robin Shane sold Aug 17, 2026 35,402 shares 2 legs combined 10b5-1 plan (scheduled) filing $213K
  6. SELLEizen Joshua M, Chief Operating Officer and Chief Legal Officer sold Jul 8, 2026 5,945 shares filing $25K

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.